Page last checked 2026-08-12

Semaglutide, locally

Semaglutide near me: which one you are being offered

The word semaglutide covers two different things, and a local search mostly returns the second one. There are the approved products, each with a brand and a price list that holds in every state. Then there is a compounded copy, which a pharmacy mixes, and whose legal basis ended on a dated FDA determination. Both need a prescription.

Source: Novo Nordisk’s own terms and FDA’s own page, read 2026-08-12

What matters first

Approved products: Ozempic, Wegovy pen, and Wegovy tablet
Compounded copy: Semaglutide is not on FDA’s shortage list, checked 14 August 2026.
Cash pricing: National manufacturer terms, not a local price list
FDA warning letters: 135 naming semaglutide

Start by checking whether a nearby offer is an approved product or a compounded preparation. Our clinic pilot does not yet have a semaglutide-specific match, so we do not present either Miami preview as one. To compare the local details that matter, see the location record.

Two things wear the same word

Semaglutide is sold in the United States as Ozempic, Wegovy and a tablet, all from Novo Nordisk, and all need a prescription. Novo Nordisk sells the pens and the tablet for cash through its own pharmacy at published prices.

A compounded copy is not one of those products. A pharmacy prepares it, rather than the company that holds the label, and nothing about it carries that label’s approval. That is the distinction the word hides, and it is the one a nearby offer usually turns on.

The legal basis for large-scale compounding of these two drugs was the shortage listing, and both shortages ended. The windows closed in March and May 2025.

Semaglutide is not on FDA’s shortage list, checked 14 August 2026.

Status comes from FDA’s drug shortage database on the date shown. The list changes daily. openFDA, read 2026-08-14.

Whether a particular preparation still qualifies is a question about that preparation, and nothing on this page settles it. The determinations, the salt-form problem and both closing dates are at the compounded semaglutide record.

The price question has no local answer

People searching this way usually want to know what it costs, and that is the part distance cannot help with. Novo Nordisk publishes one cash price list for the country. The same rows apply to a reader in any state, and the advertised figure is a starting strength rather than a monthly rate.

Semaglutide is the only molecule here you can take as a tablet, and the tablet is the reason the advertised prices mislead. The number people quote is the strength you start on for a month. The strength the label settles on costs twice that.

Whoever mixes a compounded copy sets its own price, and nobody publishes those figures in one place, so no page can quote them honestly. The published ladders for the pen and the tablet, each with the maker’s own conditions and the date the terms were read, are at the cost record and at the tablet’s own page.

The one thing a nearby counter does decide

Whether a counter has your strength today
Changes with where you are
A pen comes in fixed strengths, and a shop either has yours in the drawer or does not. That changes by the day and by the branch.
Who holds it: Nobody publishes it. We do not hold it, and the map panel does not either.

What FDA has already written about

FDA’s published warning letters name semaglutide more often than anything else on this site, and 135 of them are recent enough to list here. The two largest groups are telehealth services and websites, which is the half of this search that is not local at all.

A warning letter is FDA telling a company what the agency believes it found. It is not a court ruling and not proof that anyone was harmed.

A seller missing from this list is a seller FDA has published no letter about. That is all it means. Many sites selling these drugs are not registered with FDA at all, so nothing they do produces a letter in the first place.

Read from FDA’s published warning letters on 12 August 2026.

The enforcement record carries each one with FDA’s own subject line, both of its dates and its close-out column: the enforcement record. A letter is a fact about a company. It is not a ranking, and its absence is not a pass.

Questions people actually ask

Do I need a prescription to buy semaglutide?

Yes, and the rule is federal, so it reads the same in every state. That applies to the approved products and to a compounded copy alike. A seller who skips the step is not selling an approved medicine.

Is the semaglutide at a local clinic the same as Wegovy or Ozempic?

Not necessarily, and that is the question worth asking before paying. An approved product comes from the company holding the label. A pharmacy prepares a compounded copy, and FDA has raised a further problem with some of it: a salt form is a different active ingredient from the one in the approved drugs.

Can I get it cheaper by shopping around locally?

Not on the published price, which is one national list and does not move. What varies is your plan and what a clinic charges for its own service. Nobody publishes either one where you could compare them in advance.

Why do local results look so different from a search for the brand?

Because the two searches return different sellers. A brand search returns the maker and the pharmacies that stock it. A local one returns clinics offering their own preparation, which is a different product with a different legal standing.

2Scope and reviewWhat this local semaglutide record cannot cover, and how it is checked

What can change near you

No clinic is named here yet because the pilot does not have a current, semaglutide-specific match.
Whether one particular preparation is lawful is a question about that preparation. This page describes the general position and settles no single case.
This is a description of routes that exist and prices that are published. It is not advice about which one to take, and it is not medical or legal advice.
Only a licensed clinician can write a prescription. Nothing here helps anyone get a prescription.
Prices move. Every figure on the cost pages carries the date its source was read, and manufacturer terms change without notice.
Insurance is not covered in any depth, because plans differ so much that a general statement about coverage would be wrong for most readers.
State law is not covered. Pharmacy practice and telehealth rules are set state by state and they differ.

How we checked these details

Medically reviewed by Jennifer Montecillo, MD · non-practicing medical reviewer

Reviewed 2026-08-12

We name nobody as a place to buy, and no listing on this site is for sale. The shortage status and the letter counts come from federal files, read at build time, each carrying the date of its fetch. The rules are in the sourcing methodology; corrections go to contact@healthspanledger.com.

What your location changes at all — eight things people mean by the question, sorted by whether the answer moves.
Every route to semaglutide — the seven routes read against a drug with three approved products and two forms.
The compounded semaglutide record — the determinations, the salt-form problem and both deadlines.
The semaglutide evidence guide — what the molecule is and what the trials measured.

Sources

21 U.S.C. § 353(b) — the provision that makes these drugs prescription-only · United States Code, 2023 Edition — via GovInfo · retrieved 2026-08-12
FDA warning letters — the published enforcement record, searchable by company and by text · U.S. Food and Drug Administration · retrieved 2026-08-12
BeSafeRx — FDA’s guidance on buying medicine from a website · U.S. Food and Drug Administration · retrieved 2026-08-12
FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of 06/15/2026) · U.S. Food and Drug Administration · retrieved 2026-08-12
FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (content current as of 04/01/2026) · U.S. Food and Drug Administration · retrieved 2026-08-12
FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (news release, April 30, 2026) · U.S. Food and Drug Administration · retrieved 2026-08-12

The pages behind this one

The Ozempic price with a plan that covers it

Every Ozempic card here shuts out Medicare and Medicaid, quoted from the terms rather than paraphrased.

The Wegovy price with a plan that covers it

Every Wegovy card here shuts out Medicare and Medicaid, quoted from the terms rather than paraphrased.

What decides whether a plan pays

4 gates decide it, and a claim that fails one never reaches the next.

What a prescription actually takes

No seller is named, ranked or linked anywhere in the section, and no field in the page could hold one.

Dates, dockets and documents rather than commentary

Nothing is written in the future tense about a date that has already passed.

How every row is checked

The source definitions, citation rules and automated checks used before a figure is published.